Skip to content
Alivexis, Inc.
Unveiling the Future of Medicine
Menu
Home
Science
Pipeline
About Us
News
Public Notice
Contact Us
日本語
News
News
Modulus Discovery Announces Research Collaboration with Fujitsu on the Implementation and Optimization of ModBind™, A Novel Computational Technology for Drug Discovery
- 08 August, 2022
Modulus Discovery Closes $20.4M USD Series C
- 01 March, 2022
40th Annual J.P. Morgan Healthcare Conference - Modulus Discovery Presentation
- 14 January, 2022
Nissan Chemical and Modulus Discovery Jointly Announce Signing of Strategic Drug Discovery Collaboration Agreement
- 21 April, 2021
39th Annual J.P. Morgan Healthcare Conference - Modulus Discovery Presentation
- 26 January, 2021
Modulus Discovery, Inc. to Present at the 39th Annual J.P. Morgan Healthcare Conference
- 14 December, 2020
Modulus Discovery Announces Signing of a Collaboration Agreement with the University Of Tokyo to Pursue Drug Discovery for COVID-19 and Related Emerging Virus Infections
- 02 October, 2020
Modulus Discovery Receives “Mizuho Innovation Award”
- 28 July, 2020
Modulus Discovery Closes $25.5M USD Series B
- 13 May, 2020
Modulus Discovery Announces Signing of Research Data Transfer Agreement with Astellas Pharma Inc.
- 30 May, 2019
Previous
Next
Press & Media Contact
Email address protected by JavaScript.
Please enable JavaScript to contact me.
Latest Release
Alivexis to present ModBind™ at MACNICA booth at the AI EXPO Tokyo
Cathepsin C Inhibitor Proved Effective in the Treatment of Vasculitis~Expectations for a Novel Therapeutic Agent for ANCA-Associated Vasculitis~
Melodia Therapeutics and Alivexis Sign Exclusive License Agreement for Cathepsin C Inhibitor Program MOD-A
Alivexis with Astellas Pharma Inc. to Collaborate on Novel Drug Target
Joint Research on Novel Anti-Allergic Disease Drug Candidate Published by Alivexis, Inc. and University of Yamanashi